NASDAQ:INZY

Inozyme Pharma - INZY Stock Forecast, Price & News

$3.04

+0.28 (+10.14%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.76
▼
$3.18
50-Day Range: $1.71
▼
$3.25
52-Week Range: $0.99
▼
$6.25

Volume: 837,730 shs
Average Volume: 1.60 million shs
Market Capitalization: $122.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.75

Institutional Ownership

Inozyme Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 483.9% Upside
$17.75 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.84) to ($1.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

583rd out of 983 stocks

Pharmaceutical Preparations Industry

280th out of 478 stocks

3.4

Analyst's Opinion

Consensus Rating
Inozyme Pharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.75, Inozyme Pharma has a forecasted upside of 483.9% from its current price of $3.04.
Amount of Analyst Coverage
Inozyme Pharma has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for INZY.

0.0

Dividend Strength

Dividend Yield
Inozyme Pharma does not currently pay a dividend.
Dividend Growth
Inozyme Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INZY.

2.7

News and Social Media Coverage

News Sentiment
Inozyme Pharma has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.
Search Interest
Only 25 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inozyme Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.72% of the stock of Inozyme Pharma is held by insiders.
Percentage Held by Institutions
76.35% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.84) to ($1.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inozyme Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inozyme Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inozyme Pharma has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inozyme Pharma (NASDAQ:INZY) Stock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

March 16, 2023 | finance.yahoo.com

Why Earnings Season Could Be Great for Inozyme (INZY)

March 1, 2023 | finance.yahoo.com

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

March 22, 2023 | Upexi, Inc (Ad)

Could This Be The Biggest Stock Of 2023?

This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!

February 24, 2023 | finance.yahoo.com

Why Inozyme Pharma (INZY) Shares Are Trading Higher Today

February 22, 2023 | benzinga.com

Short Volatility Alert: Inozyme Pharma Inc

February 16, 2023 | markets.businessinsider.com

Needham Reaffirms Their Buy Rating on Inozyme Pharma (INZY)

February 16, 2023 | finanznachrichten.de

Inozyme Pharma Inc.: Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

February 16, 2023 | marketwatch.com

Inozyme Pharma Shares Rise 38% After Positive Trial Data for INZ-701

March 22, 2023 | Upexi, Inc (Ad)

Could This Be The Biggest Stock Of 2023?

This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!

February 16, 2023 | msn.com

Inozyme adds 36% on Phase 1/2 data for lead asset and cash runway

February 16, 2023 | msn.com

INZY Soars on Promising INZ-701 Data

February 16, 2023 | msn.com

Inozyme Pharma up 31% on phase 1/2 data for blood vessel disorder

February 16, 2023 | finance.yahoo.com

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

February 6, 2023 | finance.yahoo.com

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

February 4, 2023 | finance.yahoo.com

Institutions profited after Inozyme Pharma, Inc.'s (NASDAQ:INZY) market cap rose US$19m last week butprivate equity firms profited the most

January 24, 2023 | seekingalpha.com

INZY Inozyme Pharma, Inc.

January 9, 2023 | finance.yahoo.com

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

December 5, 2022 | finance.yahoo.com

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

December 1, 2022 | finance.yahoo.com

Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

November 10, 2022 | finance.yahoo.com

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 7, 2022 | finance.yahoo.com

Inozyme Pharma to Participate in Upcoming Investor Conferences

November 6, 2022 | finance.yahoo.com

Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$11m market cap decline means a loss of US$268k for insiders who bought this year

November 3, 2022 | finance.yahoo.com

Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

October 31, 2022 | finance.yahoo.com

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

September 26, 2022 | finance.yahoo.com

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

September 6, 2022 | finance.yahoo.com

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 17, 2022 | finance.yahoo.com

Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Company Calendar

Last Earnings: 11/09/2021
Today: 3/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INZY
CUSIP: N/A
CIK: 1693011
Web: www.inozyme.com
Phone: 857-330-4340
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.75
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +483.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,620,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.20%
Return on Assets: -49.06%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 11.11
Quick Ratio: 11.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.62 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 40,390,000
Free Float: 36,468,000
Market Cap: $122.79 million
Optionable: Not Optionable
Beta: 0.79

Key Executives

Mr. Axel Bolte M.B.A. (Age 50)
M.Sc., Co-Founder, Pres, CEO & Director
Comp: $889.66k

Mr. Henric Bjorn Bjarke (Age 55)
Sr. VP & COO
Comp: $597.68k

Dr. Demetrios Braddock M.D.
Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer

Mr. Sanjay S. Subramanian M.B.A. (Age 45)
M.S., CFO & Principal Accounting Officer

Dr. Soojin Kim Ph.D.
Sr. VP & Chief Technical Operations Officer

Dr. Yves Sabbagh Ph.D.
Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer

Mr. Stefan Riley
Director of Investor Relations

Ms. Gayle Gironda
Sr. VP & Chief People Officer

Dr. David Thompson M.A.
M.S., Ph.D., Chief Devel. Officer

Mr. Stephen J. Di Palma M.B.A (Age 63)
M.B.A., Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INZY Stock - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings or view top-rated stocks.
What is Inozyme Pharma's stock price forecast for 2023?: 4 Wall Street research analysts have issued 1 year target prices for Inozyme Pharma's stock. Their INZY share price forecasts range from $5.00 to $23.00. On average, they predict the company's stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 483.9% from the stock's current price.
View analysts price targets for INZY or view top-rated stocks among Wall Street analysts.
How have INZY shares performed in 2023?: Inozyme Pharma's stock was trading at $1.05 at the beginning of the year. Since then, INZY shares have increased by 189.5% and is now trading at $3.04.
View the best growth stocks for 2023 here.
How were Inozyme Pharma's earnings last quarter?: Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.01.
What other stocks do shareholders of Inozyme Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Honeywell International (HON), Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).
When did Inozyme Pharma IPO?: (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Inozyme Pharma's stock symbol?: Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY."
Who are Inozyme Pharma's major shareholders?: Inozyme Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (6.04%), Sphera Funds Management LTD. (4.02%), Millennium Management LLC (0.74%), Renaissance Technologies LLC (0.64%), State of Wisconsin Investment Board (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner.
View institutional ownership trends.
How do I buy shares of Inozyme Pharma?: Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inozyme Pharma's stock price today?: One share of INZY stock can currently be purchased for approximately $3.04.
How much money does Inozyme Pharma make?: Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $122.79 million. The company earns $-56,620,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.
How can I contact Inozyme Pharma?: The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com.

This page (NASDAQ:INZY) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inozyme Pharma - INZY Stock Forecast, Price & News

Inozyme Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inozyme Pharma (NASDAQ:INZY) Stock

INZY Stock News Headlines

INZY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

INZY Stock - Frequently Asked Questions

Overall MarketRank^™